IP Library Granted Patent US 9,376,466
Granted Patent B2
US 9,376,466 · App. 14/201,132 · Granted Jun 28, 2016

Peptide inhibitors of caspase 2 activation

Inventor: Carol M. Troy (Hastings-on-Hudson, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C07K7/06A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,376,466
App. No.
14/201,132
Granted
Jun 28, 2016
Kind
B2
Abstract

The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.

Claims (6)

1. A Caspase 2 activation inhibitor composition consisting of the amino acid sequence AFDAFC (SEQ ID NO: 1) conjugated to a cell penetrating peptide selected from the group consisting of Penetratin1, transportan, pIS1, Tat(48-60), pVEC, R16, RVGRRRRRRRRR (SEQ ID NO: 4), MPS, and KLALKLALKALKAALKLA-amide (SEQ ID NO: 10).

2. The composition of claim 1 , wherein the cell-penetrating peptide is Penetratin1.

3. A method of treating a neurodegenerative condition comprising administering, intranasally, an effective amount of a Caspase 2 activation inhibitor composition consisting of the amino acid sequence AFDAFC (SEQ ID NO: 1) conjugated to a cell penetrating peptide selected from the group consisting of Penetratin1, transportan, pIS1, Tat(48-60), pVEC, R16, RVGRRRRRRRRR (SEQ ID NO: 4), MPS, and KLALKLALKALKAALKLA-amide (SEQ ID NO: 10) to a subject in need thereof, wherein the neurodegenerative condition is treated by such administration.

4. The method of claim 3 , wherein the neurodegenerative condition is selected from the group consisting of: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.

5. A method of inhibiting a neurodegenerative condition associated with apoptosis in the central nervous system comprising administering, intranasally, an effective amount of the Caspase 2 activation inhibitor composition consisting of the amino acid sequence AFDAFC (SEQ ID NO: 1) conjugated to a cell penetrating peptide selected from the group consisting of Penetratin1, transportan, pIS1, Tat(48-60), pVEC, R16, RVGRRRRRRRRR (SEQ ID NO: 4), MPS, and KLALKLALKALKAALKLA-amide (SEQ ID NO: 10) to a subject in need thereof.

6. The method of claim 5 , wherein the cell-penetrating peptide is Penetratin1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: TROY, CAROL M.
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 036381/0927 →
CONFIRMATORY LICENSE Recorded Jul 25, 2014
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033419/0355 →
CONFIRMATORY LICENSE Recorded Jul 23, 2014
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033391/0256 →
Continuity (3)
Continuation PCTUS2012054269 · Sep 7, 2012
Provisional Application 61532717 · Sep 9, 2011
Related Publication 20150148302A1 · May 28, 2015